```html

Xanthoma Tendinous: A Complete Guide

What is Xanthoma Tendinous?

A xanthoma tendinous (also called a tendon xanthoma) is a yellow‑orange, soft‑to‑firm nodule that forms within a tendon, most often the Achilles tendon, extensor tendons of the hands, or the tendons around the elbow. The lesion is composed of collections of lipid‑laden macrophages (foam cells) that infiltrate the connective tissue of the tendon. Although the nodule itself is benign, its presence is a red flag for underlying disorders of lipid metabolism, especially familial hypercholesterolemia (FH). Recognizing tendon xanthomas can lead to early detection of serious cardiovascular disease.

Common Causes

Several metabolic and systemic conditions can produce tendon xanthomas. The most frequent include:

• Familial hypercholesterolemia (FH): An autosomal‑dominant genetic defect in LDL‑receptor, APOB, or PCSK9 leading to markedly elevated LDL‑cholesterol.
• Familial combined hyperlipidemia: Elevated LDL‑C and triglycerides due to polygenic inheritance.
• Familial dysbetalipoproteinemia (type III hyperlipoproteinemia): Defective apoE leads to accumulation of remnant particles.
• Sitosterolemia: A rare plant‑sterol absorption disorder that raises plant sterol and LDL levels.
• Secondary hyperlipidemia: Due to uncontrolled diabetes, hypothyroidism, or chronic nephrotic syndrome.
• Cholesterol‑lowering drug reactions: Rarely, long‑term high‑dose statins can provoke xanthoma‑like changes, usually after treatment interruption.
• Primary biliary cholangitis: Cholestasis can cause lipid abnormalities and occasional tendon xanthomas.
• Rare storage diseases: Such as Niemann‑Pick type C, which can deposit lipids in tendons.
• Post‑traumatic or localized lipid deposition: Very uncommon; usually related to repeated micro‑injury in athletes.
• Idiopathic: In a small minority, no identifiable lipid disorder is found.

Associated Symptoms

Tendon xanthomas are often silent, but patients may notice:

• Visible, yellow‑orange nodules on the Achilles tendon, knuckles, or extensor tendons of the fingers.
• Firmness or thickening of the affected tendon, sometimes limiting flexibility.
• Occasional pain or a feeling of “tightness,” especially after prolonged standing or activity.
• Skin xanthomas elsewhere (e.g., eruptive or tuberous xanthomas on elbows, knees, buttocks).
• Signs of hyperlipidemia: premature coronary artery disease, chest pain, or a family history of early heart attacks.
• Systemic features of the underlying disease (e.g., thyroid enlargement in hypothyroidism, edema in nephrotic syndrome).

When to See a Doctor

Prompt evaluation is warranted if any of the following occur:

• New, unexplained nodules appear on a tendon or become larger over weeks‑months.
• Accompanying pain, swelling, or loss of function in the affected joint.
• Personal or family history of early heart attacks (men < 55 y, women < 65 y) or known high cholesterol.
• Signs of systemic disease (e.g., unexplained weight gain, fatigue, swelling, or thyroid changes).
• Any rapid growth or ulceration of the nodule—though rare, this should trigger urgent assessment.

Diagnosis

Clinical Examination

Doctors begin with a focused physical exam, noting the size, color, consistency, and location of the lesions. Tendon xanthomas are typically:

• Yellow‑orange to flesh‑colored.
• Firm but not hard like calcifications.
• Symmetrical when related to FH (e.g., both Achilles tendons).

Laboratory Tests

• Lipid panel: Total cholesterol, LDL‑C, HDL‑C, triglycerides. In FH, LDL‑C is often >190 mg/dL in adults.
• Genetic testing for LDL‑R, APOB, or PCSK9 mutations (especially if FH is suspected).
• Thyroid function tests, fasting glucose/HbA1c, and urine protein to rule out secondary causes.

Imaging Studies

• Ultrasound: Shows hyperechoic, thickened tendon with heterogeneous texture.
• MRI: Provides detailed anatomy; xanthomas appear as high‑signal lesions on T2‑weighted images.
• CT scan: Occasionally used to differentiate calcific tendinopathy from xanthoma.

Histopathology (Rare)

When the diagnosis is uncertain, a fine‑needle aspirate or excisional biopsy can be performed. Microscopy reveals lipid‑laden macrophages (foam cells) within the tendon matrix.

Treatment Options

Address the Underlying Lipid Disorder

• Statins (HMG‑CoA reductase inhibitors): First‑line therapy to lower LDL‑C. High‑intensity statins (e.g., rosuvastatin 20‑40 mg) are recommended for FH.
• PCSK9 inhibitors (evolocumab, alirocumab): Reduce LDL‑C by 50‑60 % and are especially useful when statins are insufficient or not tolerated.
• Ezetimibe: Blocks intestinal cholesterol absorption; often added to statin therapy.
• Lipid apheresis: In severe homozygous FH, bi‑weekly filtration of plasma can dramatically lower LDL‑C.
• Diet & lifestyle: Plant‑based diet, soluble fiber, omega‑3 fatty acids, regular aerobic exercise, and weight control.

Local Management of the Tendon Lesion

• Observation: If lesions are asymptomatic, many clinicians recommend watchful waiting while lipid levels are optimized.
• Physical therapy: Stretching and strengthening programs improve tendon flexibility and reduce discomfort.
• Surgical excision: Considered when the nodule causes functional limitation, persistent pain, or cosmetic concern. Recurrence is possible if lipid levels remain uncontrolled.
• Laser or cryotherapy: Experimental; limited data.

Management of Associated Cardiovascular Risk

Because tendon xanthomas are a marker for premature atherosclerosis, patients often need:

• Low‑dose aspirin (if not contraindicated).
• Blood pressure control.
• Smoking cessation programs.
• Regular cardiovascular screening (e.g., coronary calcium scoring, stress testing) based on risk assessment.

Prevention Tips

• Screen family members: First‑degree relatives of a person with FH should have lipid panels and genetic testing early (ideally before age 10).
• Adopt heart‑healthy eating: Emphasize fruits, vegetables, whole grains, legumes, nuts, and fish; limit saturated fat, trans‑fat, and cholesterol.
• Maintain a healthy weight: Obesity worsens lipid profiles and puts extra load on tendons.
• Exercise regularly: At least 150 minutes of moderate‑intensity aerobic activity per week plus strength training.
• Control secondary causes: Manage diabetes, hypothyroidism, and kidney disease aggressively.
• Adhere to medication: Do not skip statins or other lipid‑lowering agents; discuss side effects with your physician instead of stopping abruptly.
• Regular check‑ups: Annual lipid panels for high‑risk individuals; more frequent monitoring when on high‑intensity therapy.

Emergency Warning Signs

If you experience any of the following, seek immediate medical attention (call 911 or go to the nearest emergency department):

• Sudden, severe chest pain radiating to the arm, jaw, or back – possible myocardial infarction.
• Sudden shortness of breath, wheezing, or feeling faint – could indicate a heart or lung emergency.
• Rapid swelling or a hot, red area over a tendon xanthoma – may signal infection (cellulitis) or an abscess.
• Sudden loss of vision or neurological symptoms – could be a stroke, especially in patients with high cholesterol.
• Unexplained severe leg pain or inability to walk – may be a tendon rupture or severe vascular compromise.

Key Take‑aways

Tendon xanthomas are more than a cosmetic issue; they are a visible clue that the body’s lipid metabolism is out of balance and that the cardiovascular system may be at risk. Early identification, thorough evaluation, and aggressive lipid‑lowering therapy can halt progression, improve tendon health, and most importantly, reduce the chance of heart attacks and strokes. If you notice any tendon nodules or have a family history of high cholesterol, talk to your healthcare provider promptly.

References:

• Mayo Clinic. “Xanthomas.” Updated 2023. https://www.mayoclinic.org
• National Heart, Lung, & Blood Institute. “Familial Hypercholesterolemia.” 2022. https://www.nhlbi.nih.gov
• Cleveland Clinic. “Tendon Xanthoma.” 2023. https://my.clevelandclinic.org
• American Heart Association. “Guidelines for the Management of Blood Cholesterol.” 2022. https://www.heart.org
• World Health Organization. “Non‑communicable diseases: Cardiovascular diseases.” 2021. https://www.who.int

```